Tandem Diabetes Care, Inc. (TNDM) Stock
Fundamentals
Source: third-party data provider, as of October 9, 2026
Compare with TNDM
Recent news
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
TNDM
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
TNDM
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
TNDM
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDMNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.13
- MACD 12/26/9
- -0.89
- EMA 9 of MACD
- -0.94
- MACD histogram
- 0.05
- SMA 50
- $19.39
- Price below SMA 50
- EMA 50
- $17.98
- Price below EMA 50
- SMA 200
- $19.32
- Price below SMA 200
- EMA 200
- $18.99
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 7 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.31 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
TNDMTandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
TNDMTandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
TNDMReasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
TNDM
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
TNDM
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care Q2 Earnings Call Highlights
TNDM
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates
TNDM
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
TNDM
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
TNDMNews tone: automated (AI) classification of the article's content, not a price prediction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John F. Sheridan | President, CEO & Director | 1955 |
| Ms. Leigh A. Vosseller | Executive VP, CFO & Treasurer | 1973 |
| Ms. Shannon M. Hansen J.D. | Executive VP, Chief Legal, Privacy & Compliance Officer and Secretary | 1966 |
| Ms. Elizabeth Anne Gasser | Executive VP and Chief Strategy & Product Officer | 1976 |
| Mr. Jean-Claude E. Kyrillos | Executive VP & COO | 1964 |
| Mr. Rick A. Carpenter | Executive VP & CTO | 1963 |
| Ms. Susan M. Morrison | Executive VP & Chief Administrative Officer | 1979 |
| Mr. Tom Fox | Executive VP & Chief Human Resources Officer | — |
| Dr. Jordan Pinsker M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Source: third-party data provider, as of October 9, 2026
Technical indicators
- RSI 14
- 35.13
- MACD 12/26/9
- -0.89
- EMA 9 of MACD
- -0.94
- MACD histogram
- 0.05
- SMA 50
- $19.39
- Price below SMA 50
- EMA 50
- $17.98
- Price below EMA 50
- SMA 200
- $19.32
- Price below SMA 200
- EMA 200
- $18.99
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 8, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $18.00
- Average
- $21.67
- High
- $28.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +6.2 | -6.0 | +20.7 | |||||||||
| 2022 | -21.3 | -6.2 | +2.9 | -20.3 | -30.3 | -9.9 | +7.1 | -29.9 | +7.3 | +11.0 | -24.9 | +5.5 |
| 2023 | -8.6 | -13.4 | +10.6 | +0.4 | -35.0 | -0.1 | +41.6 | -15.2 | -25.4 | -21.3 | +14.0 | +39.6 |
| 2024 | -19.5 | +12.5 | +28.4 | +8.4 | +41.5 | -22.5 | -6.3 | +23.5 | +1.5 | -23.6 | -4.0 | +10.8 |
| 2025 | +3.4 | -39.2 | -7.8 | -10.0 | -0.8 | -7.8 | -9.6 | -18.8 | -5.0 | +12.8 | +46.3 | +7.2 |
| 2026 | -7.7 | +25.9 | -24.0 | +3.8 | -11.4 | -21.1 | +23.8 | +9.4 | -23.4 | -4.0 |
